首页 > 最新文献

Medical sciences (Basel, Switzerland)最新文献

英文 中文
AI-Driven Innovations in Transfusion Medicine: A Narrative Synthesis of Current Reviews. 输血医学中人工智能驱动的创新:当前综述的叙述性综合。
IF 4.4 Q1 Medicine Pub Date : 2025-12-25 DOI: 10.3390/medsci14010010
Daniele Giansanti, Claudia Cosenza

Background: Recent advancements in blood transfusion and transfusion medicine have increasingly integrated innovative technologies, including artificial intelligence (AI), machine learning, and computational intelligence. Despite numerous reviews on these topics, a comprehensive synthesis of the existing evidence is lacking. Objective: This narrative review of reviews aims to summarize and critically appraise the current literature on AI-driven and emerging technological approaches in blood transfusion, providing a structured overview for researchers and clinicians. Methods: A total of 19 reviews were selected through a systematic search strategy. Studies were assessed for methodological quality, scope, and clinical relevance, using adapted criteria from narrative review checklists. Data were extracted regarding the type of technology, application in transfusion medicine, study population, and reported outcomes. Results: The included reviews highlight several key domains: AI-assisted prediction of transfusion requirements, automated blood typing and crossmatching, advanced monitoring of blood products, and integration of computational models in blood banking workflows. Most studies reported promising applications but revealed substantial heterogeneity in methods, limited clinical validation, and variable reporting quality. Conclusions: AI and emerging technologies offer significant potential to improve the safety, efficiency, and personalization of blood transfusion. However, standardization of study designs, comprehensive validation, and robust reporting are essential to translate these innovations into routine clinical practice. This review of reviews provides a structured synthesis to guide future research and implementation strategies in transfusion medicine.

背景:近年来输血和输血医学的进展越来越多地融合了创新技术,包括人工智能(AI)、机器学习和计算智能。尽管对这些主题进行了大量评论,但缺乏对现有证据的全面综合。目的:本综述旨在总结和批判性评价当前关于人工智能驱动和新兴输血技术方法的文献,为研究人员和临床医生提供一个结构化的概述。方法:采用系统检索策略,选取19篇综述。研究的方法学质量、范围和临床相关性采用叙述性回顾检查表的改编标准进行评估。提取有关技术类型、在输血医学中的应用、研究人群和报告结果的数据。结果:纳入的综述强调了几个关键领域:人工智能辅助输血需求预测、自动血型和交叉配型、血液制品的高级监测以及血库工作流程中计算模型的集成。大多数研究报告了有希望的应用,但在方法上存在很大的异质性,有限的临床验证和可变的报告质量。结论:人工智能和新兴技术为提高输血的安全性、效率和个性化提供了巨大的潜力。然而,标准化的研究设计、全面的验证和可靠的报告对于将这些创新转化为常规临床实践至关重要。这篇综述综述提供了一个结构化的综合,以指导未来的研究和输血医学的实施策略。
{"title":"AI-Driven Innovations in Transfusion Medicine: A Narrative Synthesis of Current Reviews.","authors":"Daniele Giansanti, Claudia Cosenza","doi":"10.3390/medsci14010010","DOIUrl":"10.3390/medsci14010010","url":null,"abstract":"<p><p><b>Background:</b> Recent advancements in blood transfusion and transfusion medicine have increasingly integrated innovative technologies, including artificial intelligence (AI), machine learning, and computational intelligence. Despite numerous reviews on these topics, a comprehensive synthesis of the existing evidence is lacking. <b>Objective:</b> This narrative review of reviews aims to summarize and critically appraise the current literature on AI-driven and emerging technological approaches in blood transfusion, providing a structured overview for researchers and clinicians. <b>Methods:</b> A total of 19 reviews were selected through a systematic search strategy. Studies were assessed for methodological quality, scope, and clinical relevance, using adapted criteria from narrative review checklists. Data were extracted regarding the type of technology, application in transfusion medicine, study population, and reported outcomes. <b>Results:</b> The included reviews highlight several key domains: AI-assisted prediction of transfusion requirements, automated blood typing and crossmatching, advanced monitoring of blood products, and integration of computational models in blood banking workflows. Most studies reported promising applications but revealed substantial heterogeneity in methods, limited clinical validation, and variable reporting quality. <b>Conclusions:</b> AI and emerging technologies offer significant potential to improve the safety, efficiency, and personalization of blood transfusion. However, standardization of study designs, comprehensive validation, and robust reporting are essential to translate these innovations into routine clinical practice. This review of reviews provides a structured synthesis to guide future research and implementation strategies in transfusion medicine.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consequences of Hypoxic Events, Necrosis, and Microvascular Density, in Astrocytoma IDH-Mutant, CNS WHO Grade 4. 星形细胞瘤idh突变的缺氧事件、坏死和微血管密度的后果,CNS WHO分级4级。
IF 4.4 Q1 Medicine Pub Date : 2025-12-23 DOI: 10.3390/medsci14010006
Cristian Ionut Orasanu, Madalina Bosoteanu, Sorin Vamesu, Raluca Ioana Voda, Anamaria Sincu, Mariana Deacu

Background/Objectives: Astrocytoma IDH-mutant CNS WHO grade 4 is a malignant tumor of the central nervous system characterized by tumor necrosis, microvascular proliferation, and/or homozygous CDKN2A/B deletion. This study aims to investigate the prognostic role of the consequences of hypoxic events leading to necrosis and microvascular density, observing their associations with clinical-imaging parameters and morphogenetics. Methods: We performed a retrospective analysis over a 10-year period. Clinical and imaging data were collected from observation sheets and electronic databases. Six immunohistochemical markers and FISH testing were used to evaluate the prognosis and neoformation of blood vessels. Based on the whole slide image, the necrotic percentage was assessed, and the microvascular density was quantified. All data were statistically analyzed. Results: We identified 44 cases, with a mean age of 57.86 years. From a clinical perspective, advanced age, arterial hypertension, diabetes mellitus, and acute onset of clinical manifestations represent negative prognostic factors. In imaging, the increased rate of resectability is a protective factor, while the presence of residual volume and an increased residual volume have a negative impact on survival. The consequences of hypoxic events (tumor necrosis and microvascular density) are negative risk factors for survival. Added to these are p53 overexpression, loss of PTEN, deletion, and amplification of the CDKN2A gene. Conclusions: We observed that necrosis and increased microvascular density resulting from microvascular proliferation are both defining features of the tumor and impact patient prognosis and survival. In addition, they induce or are associated with other essential changes (p53, PTEN, CDKN2A) that promote tumor aggressiveness.

背景/目的:星形细胞瘤IDH-mutant CNS WHO 4级是一种以肿瘤坏死、微血管增生和/或CDKN2A/B纯合子缺失为特征的中枢神经系统恶性肿瘤。本研究旨在探讨缺氧事件导致坏死和微血管密度的预后作用,观察其与临床影像学参数和形态遗传学的关系。方法:我们进行了为期10年的回顾性分析。临床和影像学资料收集自观察表和电子数据库。采用6种免疫组化标志物及FISH检测评价预后及血管新生情况。根据整个切片图像,评估坏死百分率,定量微血管密度。所有资料均进行统计学分析。结果:44例,平均年龄57.86岁。从临床角度看,高龄、高血压、糖尿病、急性发作的临床表现是不良预后因素。在影像学上,可切除率的增加是一个保护因素,而残余体积的存在和残余体积的增加对生存有负面影响。缺氧事件的后果(肿瘤坏死和微血管密度)是生存的负面危险因素。除此之外,还有p53过表达、PTEN缺失、CDKN2A基因缺失和扩增。结论:我们观察到由微血管增殖引起的坏死和微血管密度增加是肿瘤的决定性特征,并影响患者的预后和生存。此外,它们诱导或与其他促进肿瘤侵袭性的基本变化(p53, PTEN, CDKN2A)相关。
{"title":"Consequences of Hypoxic Events, Necrosis, and Microvascular Density, in Astrocytoma IDH-Mutant, CNS WHO Grade 4.","authors":"Cristian Ionut Orasanu, Madalina Bosoteanu, Sorin Vamesu, Raluca Ioana Voda, Anamaria Sincu, Mariana Deacu","doi":"10.3390/medsci14010006","DOIUrl":"10.3390/medsci14010006","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Astrocytoma IDH-mutant CNS WHO grade 4 is a malignant tumor of the central nervous system characterized by tumor necrosis, microvascular proliferation, and/or homozygous CDKN2A/B deletion. This study aims to investigate the prognostic role of the consequences of hypoxic events leading to necrosis and microvascular density, observing their associations with clinical-imaging parameters and morphogenetics. <b>Methods:</b> We performed a retrospective analysis over a 10-year period. Clinical and imaging data were collected from observation sheets and electronic databases. Six immunohistochemical markers and FISH testing were used to evaluate the prognosis and neoformation of blood vessels. Based on the whole slide image, the necrotic percentage was assessed, and the microvascular density was quantified. All data were statistically analyzed. <b>Results:</b> We identified 44 cases, with a mean age of 57.86 years. From a clinical perspective, advanced age, arterial hypertension, diabetes mellitus, and acute onset of clinical manifestations represent negative prognostic factors. In imaging, the increased rate of resectability is a protective factor, while the presence of residual volume and an increased residual volume have a negative impact on survival. The consequences of hypoxic events (tumor necrosis and microvascular density) are negative risk factors for survival. Added to these are p53 overexpression, loss of PTEN, deletion, and amplification of the CDKN2A gene. <b>Conclusions:</b> We observed that necrosis and increased microvascular density resulting from microvascular proliferation are both defining features of the tumor and impact patient prognosis and survival. In addition, they induce or are associated with other essential changes (p53, PTEN, CDKN2A) that promote tumor aggressiveness.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Combined General Anesthesia and Epidural Analgesia on Postoperative Pulmonary Complications in Thoracoscopic Esophagectomy. 全麻联合硬膜外镇痛对胸腔镜食管切除术术后肺部并发症的影响。
IF 4.4 Q1 Medicine Pub Date : 2025-12-23 DOI: 10.3390/medsci14010007
Hiroyuki Kitagawa, Keiichiro Yokota, Kento Shinnou, Kohei Araki, Norihiro Nishiyama, Hiromichi Maeda, Tsutomu Namikawa, Satoru Seo

Background and Aims: Although combined general anesthesia and epidural analgesia are used in open surgery to promote rehabilitation and expectoration, as well as to prevent postoperative pulmonary complications, their effect in thoracoscopic esophagectomy remains unclear. This study aimed to address this issue. Patients and Methods: We enrolled 150 patients who underwent thoracoscopic esophagectomy between May 2017 and July 2025. Patient characteristics and postoperative outcomes, including maximum numerical rating scale (NRS) after surgery and pneumonia, were compared between the use and non-use of epidural analgesia. Epidural analgesia was not administered in patients using antithrombotic/anticoagulant drugs or in those with a history of thoracic spine surgery. Postoperative analgesia involved the scheduled administration of acetaminophen in all cases, with patient-controlled analgesia using opioids administered to the non-epidural analgesia group. Results: Epidural analgesia was administered to 113 patients (75.3%). The most common levels of epidural catheter placement were Th8/Th9 in 55 patients (36.7%) and Th7/Th8 in 41 patients (27.3%). Laparoscopy was performed in 129 patients (86.0%). Median NRS was five, and pneumonia occurred in 16 patients (10.7%). The epidural anesthesia group had a higher proportion of squamous cell carcinoma (88.5% vs. 73.0%, p = 0.024), lower lymphocyte counts (1680 vs. 2065, p = 0.020), diabetes (16.8% vs. 37.8%, p = 0.007), and hypertension (54.9% vs. 81.1%, p = 0.006), and circular stapler anastomosis (83.2% vs. 62.2%, p < 0.001). No significant differences were observed in the postoperative NRS, pneumonia, or length of postoperative hospital stay. Conclusions: There was no significant difference in the postoperative NRS and pneumonia between those with or without epidural analgesia in thoracoscopic esophagectomy.

背景与目的:虽然全麻联合硬膜外镇痛在开放手术中用于促进康复和咳痰,以及预防术后肺部并发症,但其在胸腔镜食管切除术中的效果尚不清楚。本研究旨在解决这一问题。患者和方法:我们招募了150名在2017年5月至2025年7月期间接受胸腔镜食管切除术的患者。比较使用和未使用硬膜外镇痛的患者特征和术后结局,包括术后和肺炎后的最大数值评定量表(NRS)。使用抗血栓/抗凝药物的患者或有胸椎手术史的患者不使用硬膜外镇痛。所有病例术后均给予对乙酰氨基酚定时镇痛,非硬膜外镇痛组使用阿片类药物进行患者控制镇痛。结果:硬膜外镇痛113例(75.3%)。最常见的硬膜外置管水平是Th8/Th9(55例,36.7%)和Th7/Th8(41例,27.3%)。129例(86.0%)患者行腹腔镜检查。NRS中位数为5,16例(10.7%)患者发生肺炎。硬膜外麻醉组鳞状细胞癌(88.5% vs. 73.0%, p = 0.024)、淋巴细胞计数较低(1680 vs. 2065, p = 0.020)、糖尿病(16.8% vs. 37.8%, p = 0.007)、高血压(54.9% vs. 81.1%, p = 0.006)、圆形吻合器吻合术(83.2% vs. 62.2%, p < 0.001)比例较高。在术后NRS、肺炎或术后住院时间方面没有观察到显著差异。结论:胸腔镜食管切除术硬膜外镇痛与非硬膜外镇痛术后NRS及肺炎发生率无显著差异。
{"title":"The Effect of Combined General Anesthesia and Epidural Analgesia on Postoperative Pulmonary Complications in Thoracoscopic Esophagectomy.","authors":"Hiroyuki Kitagawa, Keiichiro Yokota, Kento Shinnou, Kohei Araki, Norihiro Nishiyama, Hiromichi Maeda, Tsutomu Namikawa, Satoru Seo","doi":"10.3390/medsci14010007","DOIUrl":"10.3390/medsci14010007","url":null,"abstract":"<p><p><b>Background and Aims:</b> Although combined general anesthesia and epidural analgesia are used in open surgery to promote rehabilitation and expectoration, as well as to prevent postoperative pulmonary complications, their effect in thoracoscopic esophagectomy remains unclear. This study aimed to address this issue. <b>Patients and Methods:</b> We enrolled 150 patients who underwent thoracoscopic esophagectomy between May 2017 and July 2025. Patient characteristics and postoperative outcomes, including maximum numerical rating scale (NRS) after surgery and pneumonia, were compared between the use and non-use of epidural analgesia. Epidural analgesia was not administered in patients using antithrombotic/anticoagulant drugs or in those with a history of thoracic spine surgery. Postoperative analgesia involved the scheduled administration of acetaminophen in all cases, with patient-controlled analgesia using opioids administered to the non-epidural analgesia group. <b>Results:</b> Epidural analgesia was administered to 113 patients (75.3%). The most common levels of epidural catheter placement were Th8/Th9 in 55 patients (36.7%) and Th7/Th8 in 41 patients (27.3%). Laparoscopy was performed in 129 patients (86.0%). Median NRS was five, and pneumonia occurred in 16 patients (10.7%). The epidural anesthesia group had a higher proportion of squamous cell carcinoma (88.5% vs. 73.0%, <i>p</i> = 0.024), lower lymphocyte counts (1680 vs. 2065, <i>p</i> = 0.020), diabetes (16.8% vs. 37.8%, <i>p</i> = 0.007), and hypertension (54.9% vs. 81.1%, <i>p</i> = 0.006), and circular stapler anastomosis (83.2% vs. 62.2%, <i>p</i> < 0.001). No significant differences were observed in the postoperative NRS, pneumonia, or length of postoperative hospital stay. <b>Conclusions:</b> There was no significant difference in the postoperative NRS and pneumonia between those with or without epidural analgesia in thoracoscopic esophagectomy.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lurasidone and Fluvoxamine Combination in Eating Disorders with Comorbid Obsessive-Compulsive Disorder: Preliminary Evidence from an Observational Study. 鲁拉西酮和氟伏沙明联合治疗饮食失调伴共病强迫症:一项观察性研究的初步证据。
IF 4.4 Q1 Medicine Pub Date : 2025-12-23 DOI: 10.3390/medsci14010008
Francesco Monaco, Annarita Vignapiano, Ernesta Panarello, Stefania Landi, Giuseppe Scarano, Giovanna Celia, Giulio Corrivetti, Luca Steardo, Mauro Cozzolino

Background: Anorexia nervosa (AN) and obsessive-compulsive disorder (OCD) share core features of cognitive rigidity, anxiety, and altered reward processing. Pharmacological options remain limited, and combined modulation of serotonergic and dopaminergic systems may provide new therapeutic directions. This naturalistic study explored the combined use of lurasidone and fluvoxamine in individuals with restrictive AN (AN-r) and comorbid OCD.

Methods: Forty-five female inpatients with AN-r and OCD were followed for six months. Participants received either lurasidone + fluvoxamine (n = 14) or heterogeneous SSRI/antipsychotic regimens (n = 31). Primary outcomes were the Recovery Assessment Scale (RAS) and Body Uneasiness Test Global Severity Index (BUT-GSI). Secondary outcomes included the Eating Disorder Examination-Questionnaire (EDE-Q) and Eating Disorder Inventory-3 (EDI-3). Bayesian repeated-measures ANOVAs were conducted, reporting BF10, BFInclusion, and P(M│data) values, with multiple imputation applied to manage missing data.

Results: Analyses indicated time-related changes across primary outcomes (RAS and BUT-GSI), with moderate-to-strong evidence (BF10 = 4.2-18.6) supporting overall improvement during treatment. Secondary and exploratory measures showed weaker or inconsistent trends (BF10 < 3). No evidence emerged for group-by-time interactions exceeding anecdotal strength.

Conclusions: Within the constraints of this small, all-female inpatient cohort, the findings illustrate directional, time-related changes compatible with global rehabilitation effects rather than drug-specific efficacy. The study demonstrates the feasibility-and methodological challenges-of applying Bayesian longitudinal modeling to incomplete clinical datasets. Future randomized or adaptive trials incorporating objective endpoints and data-quality pipelines are warranted to test whether serotonergic-dopaminergic-σ-1 synergy provides genuine clinical benefit in the AN-OCD spectrum.

背景:神经性厌食症(AN)和强迫症(OCD)具有认知僵化、焦虑和奖励加工改变的核心特征。药物选择仍然有限,血清素和多巴胺能系统的联合调节可能提供新的治疗方向。这项自然主义研究探讨了鲁拉西酮和氟伏沙明在限制性AN (AN-r)和共病强迫症患者中的联合应用。方法:对45例女性AN-r合并强迫症住院患者进行为期6个月的随访。参与者接受鲁拉西酮+氟伏沙明(n = 14)或异质性SSRI/抗精神病药物治疗(n = 31)。主要结果为恢复评估量表(RAS)和身体不适测试整体严重程度指数(ut - gsi)。次要结局包括饮食失调检查问卷(ed - q)和饮食失调量表-3 (edi3)。进行贝叶斯重复测量方差分析,报告BF10、bfinusion和P(M)│数据值,并采用多重输入来管理缺失数据。结果:分析显示主要结局(RAS和butt - gsi)的时间相关变化,有中等到强烈的证据(BF10 = 4.2-18.6)支持治疗期间总体改善。次要和探索性测量显示较弱或不一致的趋势(BF10 < 3)。没有证据表明群体间的互动超过传闻的强度。结论:在这个小的、全女性住院患者队列的限制下,研究结果说明了定向的、与时间相关的变化与全球康复效果相一致,而不是药物特异性疗效。该研究证明了将贝叶斯纵向建模应用于不完整临床数据集的可行性和方法学上的挑战。未来的随机或适应性试验将纳入客观终点和数据质量管道,以检验血清素能-多巴胺能-σ-1协同作用是否在AN-OCD谱系中提供真正的临床益处。
{"title":"Lurasidone and Fluvoxamine Combination in Eating Disorders with Comorbid Obsessive-Compulsive Disorder: Preliminary Evidence from an Observational Study.","authors":"Francesco Monaco, Annarita Vignapiano, Ernesta Panarello, Stefania Landi, Giuseppe Scarano, Giovanna Celia, Giulio Corrivetti, Luca Steardo, Mauro Cozzolino","doi":"10.3390/medsci14010008","DOIUrl":"10.3390/medsci14010008","url":null,"abstract":"<p><strong>Background: </strong>Anorexia nervosa (AN) and obsessive-compulsive disorder (OCD) share core features of cognitive rigidity, anxiety, and altered reward processing. Pharmacological options remain limited, and combined modulation of serotonergic and dopaminergic systems may provide new therapeutic directions. This naturalistic study explored the combined use of lurasidone and fluvoxamine in individuals with restrictive AN (AN-r) and comorbid OCD.</p><p><strong>Methods: </strong>Forty-five female inpatients with AN-r and OCD were followed for six months. Participants received either lurasidone + fluvoxamine (n = 14) or heterogeneous SSRI/antipsychotic regimens (n = 31). Primary outcomes were the <i>Recovery Assessment Scale (RAS)</i> and <i>Body Uneasiness Test Global Severity Index (BUT-GSI)</i>. Secondary outcomes included the <i>Eating Disorder Examination-Questionnaire (EDE-Q)</i> and <i>Eating Disorder Inventory-3 (EDI-3)</i>. Bayesian repeated-measures ANOVAs were conducted, reporting <i>BF</i><sub>10</sub>, BFInclusion, and P(M│data) values, with multiple imputation applied to manage missing data.</p><p><strong>Results: </strong>Analyses indicated time-related changes across primary outcomes (RAS and BUT-GSI), with moderate-to-strong evidence (<i>BF</i><sup>10</sup> = 4.2-18.6) supporting overall improvement during treatment. Secondary and exploratory measures showed weaker or inconsistent trends (<i>BF</i><sub>10</sub> < 3). No evidence emerged for group-by-time interactions exceeding anecdotal strength.</p><p><strong>Conclusions: </strong>Within the constraints of this small, all-female inpatient cohort, the findings illustrate directional, time-related changes compatible with global rehabilitation effects rather than drug-specific efficacy. The study demonstrates the feasibility-and methodological challenges-of applying Bayesian longitudinal modeling to incomplete clinical datasets. Future randomized or adaptive trials incorporating objective endpoints and data-quality pipelines are warranted to test whether serotonergic-dopaminergic-σ-1 synergy provides genuine clinical benefit in the AN-OCD spectrum.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes. 雄激素源性脱发再生疗法的前景和缺陷:富血小板血浆、光生物调节、干细胞和外泌体。
IF 4.4 Q1 Medicine Pub Date : 2025-12-22 DOI: 10.3390/medsci14010005
Aditya K Gupta, Tong Wang, Ryan Welter, Robin Unger, Ricardo Mejia

Background: Regenerative therapies have emerged in recent years. In particular, their utility in managing androgenetic alopecia-the most prevalent hair loss condition worldwide, affecting up to half of adults-is an active area of research. Navigating this space can be challenging for physicians due to widespread commercialization, lack of high-quality evidence, and an evolving regulatory landscape.

Objective: To critically review recently published evidence (2020-2025) on platelet-rich plasma, photobiomodulation, stem cells, and exosomes for the treatment of androgenetic alopecia.

Methods: A scoping review was conducted using PubMed, Embase (Ovid) and the Cochrane Controlled Register of Trials in February and November of 2025. Combination therapies were excluded.

Results and conclusions: Platelet-rich plasma is the most studied modality, with emerging investigations into newer formulations such as leukocyte-rich and pure platelet-rich plasma. However, recent studies are limited by inconsistent reporting of cellular composition, short follow-up durations, and a lack of comparative data on treatment protocols. The efficacy of photobiomodulation as a monotherapy remains debated, with inconsistent reporting of device parameters. Stem cells and exosomes show promising, though still limited, clinical evidence in inducing hair regrowth. Standardization of these therapies is crucial, with emphasis on transparency, reproducibility, and patient safety.

背景:近年来出现了再生疗法。特别是,它们在治疗雄激素性脱发方面的作用——雄激素性脱发是世界上最普遍的脱发状况,影响着多达一半的成年人——是一个活跃的研究领域。由于广泛的商业化,缺乏高质量的证据,以及不断变化的监管环境,医生在这一领域的导航可能具有挑战性。目的:对最近发表的关于富血小板血浆、光生物调节、干细胞和外泌体治疗雄激素性脱发的证据(2020-2025)进行批判性回顾。方法:于2025年2月和11月使用PubMed、Embase (Ovid)和Cochrane对照试验登记册进行范围综述。排除联合治疗。结果和结论:富血小板血浆是研究最多的一种方式,随着对富白细胞和纯富血小板血浆等新配方的研究不断涌现。然而,最近的研究受到细胞组成报告不一致、随访时间短以及缺乏治疗方案比较数据的限制。光生物调节作为单一疗法的有效性仍然存在争议,设备参数的报道不一致。干细胞和外泌体在诱导头发再生方面显示出有希望的临床证据,尽管仍然有限。这些疗法的标准化至关重要,强调透明度、可重复性和患者安全性。
{"title":"Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes.","authors":"Aditya K Gupta, Tong Wang, Ryan Welter, Robin Unger, Ricardo Mejia","doi":"10.3390/medsci14010005","DOIUrl":"10.3390/medsci14010005","url":null,"abstract":"<p><strong>Background: </strong>Regenerative therapies have emerged in recent years. In particular, their utility in managing androgenetic alopecia-the most prevalent hair loss condition worldwide, affecting up to half of adults-is an active area of research. Navigating this space can be challenging for physicians due to widespread commercialization, lack of high-quality evidence, and an evolving regulatory landscape.</p><p><strong>Objective: </strong>To critically review recently published evidence (2020-2025) on platelet-rich plasma, photobiomodulation, stem cells, and exosomes for the treatment of androgenetic alopecia.</p><p><strong>Methods: </strong>A scoping review was conducted using PubMed, Embase (Ovid) and the Cochrane Controlled Register of Trials in February and November of 2025. Combination therapies were excluded.</p><p><strong>Results and conclusions: </strong>Platelet-rich plasma is the most studied modality, with emerging investigations into newer formulations such as leukocyte-rich and pure platelet-rich plasma. However, recent studies are limited by inconsistent reporting of cellular composition, short follow-up durations, and a lack of comparative data on treatment protocols. The efficacy of photobiomodulation as a monotherapy remains debated, with inconsistent reporting of device parameters. Stem cells and exosomes show promising, though still limited, clinical evidence in inducing hair regrowth. Standardization of these therapies is crucial, with emphasis on transparency, reproducibility, and patient safety.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malformation Pattern and Molecular Findings in the FGFR1-Related Hartsfield Syndrome Phenotype. fgfr1相关Hartsfield综合征表型的畸形模式和分子发现。
IF 4.4 Q1 Medicine Pub Date : 2025-12-22 DOI: 10.3390/medsci14010004
Federica Gaudioso, Giulia Pascolini

Background/objectives: The Fibroblast Growth Factor Receptor 1 (FGFR1, MIM*136350) is a protein member of the fibroblast growth factor receptor (FGFR) family, with various biological functions, such as the normal development control. It contains an extracellular site for the ligand (three Ig-like domains, IgI, IgII, IgIII), a single transmembrane and a cytoplasmic protein tyrosine kinase (TK) domain. Variants in this gene have been associated with a wide spectrum of genetic disorders, including the clinical entity known as FGFR1-related Hartsfield or Hartsfield syndrome (HRTFDS, MIM#615465), which is an autosomal dominant or recessive disorder characterized by the clinical association of split-hand/foot malformation (SHFM) and holoprosencephaly (HPE). Dysmorphic facies, including cleft/lip palate, genitourinary anomalies, cardiovascular defects and intellectual disability/developmental delay (ID/DD) can also be a part of the clinical picture.

Methods: The malformation phenotype of HRTFDS has been reviewed in 26 previously reported patients in terms of single congenital defects, mutational spectrum, impacted protein domains and inheritance. Molecular basis, clinical management, main differential diagnoses and genetic counseling were also illustrated.

Results: SHFM was identified in every patient. The other main associated features included craniofacial defects, skeletal malformation identified at radiography, genitourinary anomalies, HPE and cardiovascular disorders. FGFR1 causative variants mainly impact the TK domain and have a smaller impact on other protein sites (IgII, IgIII).

Conclusions: This study extensively recapitulates the malformation phenotype associated with HRTFDS and the underlying molecular perturbations. A multidisciplinary clinical approach is fundamental, in which genetic counseling can have an important role. However, our results are partial and refer to a restricted number of patients, pointing out the necessity of other descriptions and similar research. Additional studies will expand clinical and molecular knowledge as well as further clarify the biological mechanisms.

背景/目的:成纤维细胞生长因子受体1 (Fibroblast Growth Factor Receptor 1, FGFR1, MIM*136350)是成纤维细胞生长因子受体(FGFR)家族的一种蛋白成员,具有多种生物学功能,如正常发育控制。它包含一个配体的细胞外位点(三个igg样结构域,IgI, IgII, IgIII),一个跨膜结构域和一个细胞质蛋白酪氨酸激酶(TK)结构域。该基因的变异与广泛的遗传疾病有关,包括临床实体fgfr1相关的Hartsfield或Hartsfield综合征(HRTFDS, MIM#615465),这是一种常染色体显性或隐性疾病,其临床特征是分手/足畸形(SHFM)和前脑畸形(HPE)。畸形相,包括唇腭裂、泌尿生殖系统异常、心血管缺陷和智力残疾/发育迟缓(ID/DD)也可能是临床症状的一部分。方法:从单个先天性缺陷、突变谱、受影响的蛋白结构域和遗传等方面对26例HRTFDS畸形表型进行回顾性分析。并简述了该病的分子基础、临床处理、主要鉴别诊断及遗传咨询。结果:所有患者均确诊为SHFM。其他主要的相关特征包括颅面缺陷、x线摄影发现的骨骼畸形、泌尿生殖系统异常、HPE和心血管疾病。FGFR1致病变异主要影响TK结构域,对其他蛋白位点的影响较小(IgII, IgIII)。结论:本研究广泛概括了与HRTFDS相关的畸形表型和潜在的分子扰动。多学科临床方法是基本的,其中遗传咨询可以发挥重要作用。然而,我们的结果是局部的,涉及的患者数量有限,指出其他描述和类似研究的必要性。进一步的研究将扩大临床和分子知识,并进一步阐明生物学机制。
{"title":"Malformation Pattern and Molecular Findings in the <i>FGFR1</i>-Related Hartsfield Syndrome Phenotype.","authors":"Federica Gaudioso, Giulia Pascolini","doi":"10.3390/medsci14010004","DOIUrl":"10.3390/medsci14010004","url":null,"abstract":"<p><strong>Background/objectives: </strong>The Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>, MIM*136350) is a protein member of the fibroblast growth factor receptor (FGFR) family, with various biological functions, such as the normal development control. It contains an extracellular site for the ligand (three Ig-like domains, IgI, IgII, IgIII), a single transmembrane and a cytoplasmic protein tyrosine kinase (TK) domain. Variants in this gene have been associated with a wide spectrum of genetic disorders, including the clinical entity known as <i>FGFR1</i>-related Hartsfield or Hartsfield syndrome (HRTFDS, MIM#615465), which is an autosomal dominant or recessive disorder characterized by the clinical association of split-hand/foot malformation (SHFM) and holoprosencephaly (HPE). Dysmorphic facies, including cleft/lip palate, genitourinary anomalies, cardiovascular defects and intellectual disability/developmental delay (ID/DD) can also be a part of the clinical picture.</p><p><strong>Methods: </strong>The malformation phenotype of HRTFDS has been reviewed in 26 previously reported patients in terms of single congenital defects, mutational spectrum, impacted protein domains and inheritance. Molecular basis, clinical management, main differential diagnoses and genetic counseling were also illustrated.</p><p><strong>Results: </strong>SHFM was identified in every patient. The other main associated features included craniofacial defects, skeletal malformation identified at radiography, genitourinary anomalies, HPE and cardiovascular disorders. <i>FGFR1</i> causative variants mainly impact the TK domain and have a smaller impact on other protein sites (IgII, IgIII).</p><p><strong>Conclusions: </strong>This study extensively recapitulates the malformation phenotype associated with HRTFDS and the underlying molecular perturbations. A multidisciplinary clinical approach is fundamental, in which genetic counseling can have an important role. However, our results are partial and refer to a restricted number of patients, pointing out the necessity of other descriptions and similar research. Additional studies will expand clinical and molecular knowledge as well as further clarify the biological mechanisms.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Drug Reaction to Linezolid in Drug-Resistant Tuberculosis: A Systematic Review. 耐药结核病对利奈唑胺的不良反应:系统综述。
IF 4.4 Q1 Medicine Pub Date : 2025-12-22 DOI: 10.3390/medsci14010003
Emy Oktaviani, Kusnandar Anggadiredja, Lia Amalia

Background/Objectives: The use of linezolid in drug-resistant tuberculosis has shown good effectiveness but has a high risk of adverse drug reactions (ADRs). Linezolid-related ADRs have been widely reported and may affect their therapeutic effect. This systematic review aimed to describe linezolid-related ADRs in drug-resistant tuberculosis. Methods: This literature review was conducted on PubMed, Scopus, ProQuest, and Sage without year limitation, up to June 2023. Study quality was assessed using the JBI checklist to evaluate method quality and risk of bias in the included articles. Inclusion criteria included studies assessing linezolid-correlated ADRs in drug-resistant tuberculosis patients with individual regimens, having access to the full text, and using the English or Indonesian language. Potential reporting bias was minimized by comprehensive database search and duplicate screening. Results: Initially, we identified 650 potential studies. Upon further assessment for relevance and eligibility, seven articles were selected for analysis. From seven articles, it was shown that all articles were reporting about linezolid-correlated ADRs. The three main ADRs are hematologic toxicity, peripheral neuropathy, and optic neuritis. In addition, gastrointestinal disorder and hyperlactatemia are reported as ADRs too. Varied doses of linezolid were used in the seven articles; they range from 300 mg to 1200 mg, with 600 mg/twice daily and 1200 mg/day being dominant. Conclusions: Linezolid-associated ADRs are dose- and duration-dependent. Hematological toxicity most commonly occurs at the beginning of treatment, while peripheral neuropathy and optic neuritis appear after long-term use. Therefore, intensive monitoring and therapeutic drug monitoring are essential to ensure the safety of linezolid therapy.

背景/目的:利奈唑胺用于耐药结核病的疗效良好,但存在较高的药物不良反应(adr)风险。利奈唑胺相关不良反应已被广泛报道,并可能影响其治疗效果。本系统综述旨在描述耐药结核病中利奈唑胺相关的不良反应。方法:本文献综述在PubMed、Scopus、ProQuest和Sage上进行,不受年份限制,截止到2023年6月。采用JBI检查表对纳入文章的方法质量和偏倚风险进行评估。纳入标准包括评估耐药结核病患者使用个别方案的利奈唑胺相关adr的研究,可获得全文,并使用英语或印尼语。通过全面的数据库搜索和重复筛选,潜在的报告偏倚被最小化。结果:最初,我们确定了650个潜在的研究。在进一步评估相关性和合格性后,选择了七篇文章进行分析。从7篇文章中,我们发现所有的文章都报道了利奈唑胺相关的adr。三种主要的不良反应是血液毒性、周围神经病变和视神经炎。此外,胃肠道疾病和高乳酸血症也被报道为不良反应。7篇文章中使用了不同剂量的利奈唑胺;它们的范围从300毫克到1200毫克,其中600毫克/每天两次和1200毫克/天占主导地位。结论:利奈唑胺相关不良反应是剂量依赖性和持续时间依赖性的。血液毒性最常见于治疗初期,而长期使用后出现周围神经病变和视神经炎。因此,加强监测和治疗药物监测对确保利奈唑胺治疗的安全性至关重要。
{"title":"Adverse Drug Reaction to Linezolid in Drug-Resistant Tuberculosis: A Systematic Review.","authors":"Emy Oktaviani, Kusnandar Anggadiredja, Lia Amalia","doi":"10.3390/medsci14010003","DOIUrl":"10.3390/medsci14010003","url":null,"abstract":"<p><p><b>Background/Objectives</b>: The use of linezolid in drug-resistant tuberculosis has shown good effectiveness but has a high risk of adverse drug reactions (ADRs). Linezolid-related ADRs have been widely reported and may affect their therapeutic effect. This systematic review aimed to describe linezolid-related ADRs in drug-resistant tuberculosis. <b>Methods</b>: This literature review was conducted on PubMed, Scopus, ProQuest, and Sage without year limitation, up to June 2023. Study quality was assessed using the JBI checklist to evaluate method quality and risk of bias in the included articles. Inclusion criteria included studies assessing linezolid-correlated ADRs in drug-resistant tuberculosis patients with individual regimens, having access to the full text, and using the English or Indonesian language. Potential reporting bias was minimized by comprehensive database search and duplicate screening. <b>Results:</b> Initially, we identified 650 potential studies. Upon further assessment for relevance and eligibility, seven articles were selected for analysis. From seven articles, it was shown that all articles were reporting about linezolid-correlated ADRs. The three main ADRs are hematologic toxicity, peripheral neuropathy, and optic neuritis. In addition, gastrointestinal disorder and hyperlactatemia are reported as ADRs too. Varied doses of linezolid were used in the seven articles; they range from 300 mg to 1200 mg, with 600 mg/twice daily and 1200 mg/day being dominant. <b>Conclusions</b>: Linezolid-associated ADRs are dose- and duration-dependent. Hematological toxicity most commonly occurs at the beginning of treatment, while peripheral neuropathy and optic neuritis appear after long-term use. Therefore, intensive monitoring and therapeutic drug monitoring are essential to ensure the safety of linezolid therapy.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Emotion Regulation and Illness Identity Shape Mental Health in Adults with Congenital Heart Disease. 情绪调节和疾病认同如何影响成人先天性心脏病患者的心理健康。
IF 4.4 Q1 Medicine Pub Date : 2025-12-19 DOI: 10.3390/medsci14010002
Anna-Lena Ehmann, Daniel T Marggrander, Janina Semmler, Felix Berger, Paul C Helm, Constanze Pfitzer

Background/Objectives: Adults with congenital heart disease (ACHD) are at increased risk for mental health problems, particularly depression and anxiety. Emerging evidence suggests that psychological rather than purely medical factors may play a decisive role in explaining individual differences in emotional adjustment. However, comprehensive models integrating multiple cognitive and emotional domains remain scarce. This study aimed to identify the psychological variables most strongly associated with depressive and anxiety symptoms in ACHD when considered simultaneously to inform priorities for psychosocial interventions. Methods: A total of 1136 ACHD (aged 18-85 years; 59.7% female) from the National Register for Congenital Heart Defects, Berlin, completed an online survey assessing depression, anxiety, emotion regulation, illness perceptions, and illness identity. Correlational and multiple regression analyses were conducted, controlling for sociodemographic characteristics, CHD severity, and secondary diseases. Significance level for regression models was set at p < 0.025 due to Bonferroni correction. Results: Rumination showed the strongest positive correlations with both depression and anxiety, whereas acceptance was most negatively correlated. In multiple regression analyses, rumination (highest unique variance explanation with semi-partial R2 = 0.068 resp. 0.072) and illness engulfment emerged as the most strongly associated predictors of depressive and anxiety symptoms. Illness-related concerns were not significant predictors. Conclusions: The findings highlight the key role of repetitive negative thinking and an engulfed illness identity in the development of emotional distress among ACHD. Psychotherapeutic interventions targeting rumination, fostering psychological distance from illness identity, and promoting a multifaceted self-concept may be particularly beneficial in this population.

背景/目的:患有先天性心脏病(ACHD)的成年人出现精神健康问题的风险增加,尤其是抑郁和焦虑。新出现的证据表明,在解释情绪调节的个体差异时,心理因素而非纯粹的医学因素可能起决定性作用。然而,整合多个认知和情感领域的综合模型仍然很少。本研究旨在确定与ACHD中抑郁和焦虑症状最密切相关的心理变量,同时考虑心理社会干预的优先事项。方法:来自柏林国家先天性心脏缺陷登记处的1136例ACHD(18-85岁,59.7%为女性)完成了一项在线调查,评估抑郁、焦虑、情绪调节、疾病感知和疾病认同。在控制社会人口学特征、冠心病严重程度和继发疾病的情况下,进行相关和多元回归分析。采用Bonferroni校正,回归模型的显著性水平为p < 0.025。结果:反刍与抑郁、焦虑呈正相关,接纳与抑郁、焦虑负相关。在多元回归分析中,反刍(半偏R2 = 0.068 resp)的唯一方差解释最高。0.072)和疾病吞噬是与抑郁和焦虑症状最相关的预测因子。与疾病相关的担忧并不是显著的预测因素。结论:研究结果强调了反复的消极思维和被吞没的疾病认同在ACHD患者情绪困扰发展中的关键作用。针对反刍的心理治疗干预,培养与疾病身份的心理距离,以及促进多方面的自我概念可能对这一人群特别有益。
{"title":"How Emotion Regulation and Illness Identity Shape Mental Health in Adults with Congenital Heart Disease.","authors":"Anna-Lena Ehmann, Daniel T Marggrander, Janina Semmler, Felix Berger, Paul C Helm, Constanze Pfitzer","doi":"10.3390/medsci14010002","DOIUrl":"10.3390/medsci14010002","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Adults with congenital heart disease (ACHD) are at increased risk for mental health problems, particularly depression and anxiety. Emerging evidence suggests that psychological rather than purely medical factors may play a decisive role in explaining individual differences in emotional adjustment. However, comprehensive models integrating multiple cognitive and emotional domains remain scarce. This study aimed to identify the psychological variables most strongly associated with depressive and anxiety symptoms in ACHD when considered simultaneously to inform priorities for psychosocial interventions. <b>Methods:</b> A total of 1136 ACHD (aged 18-85 years; 59.7% female) from the National Register for Congenital Heart Defects, Berlin, completed an online survey assessing depression, anxiety, emotion regulation, illness perceptions, and illness identity. Correlational and multiple regression analyses were conducted, controlling for sociodemographic characteristics, CHD severity, and secondary diseases. Significance level for regression models was set at <i>p</i> < 0.025 due to Bonferroni correction. <b>Results:</b> Rumination showed the strongest positive correlations with both depression and anxiety, whereas acceptance was most negatively correlated. In multiple regression analyses, rumination (highest unique variance explanation with semi-partial R<sup>2</sup> = 0.068 resp. 0.072) and illness engulfment emerged as the most strongly associated predictors of depressive and anxiety symptoms. Illness-related concerns were not significant predictors. <b>Conclusions:</b> The findings highlight the key role of repetitive negative thinking and an engulfed illness identity in the development of emotional distress among ACHD. Psychotherapeutic interventions targeting rumination, fostering psychological distance from illness identity, and promoting a multifaceted self-concept may be particularly beneficial in this population.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of the Manual Diaphragm Release Technique in Neurocritical Patients on Mechanical Ventilation: A Pilot Randomized Controlled Trial. 手动膈肌释放技术在神经危重患者机械通气中的可行性:一项随机对照试验。
IF 4.4 Q1 Medicine Pub Date : 2025-12-19 DOI: 10.3390/medsci14010001
Elis Fernanda Araújo Lima de Oliveira, Helga Cecília Muniz de Souza, Heitor Fernandes Silveira Cavalini, Fabianne Maisa de Novaes Assis Dantas, Victor Ribeiro Neves, Fernando de Aguiar Lemos, Marcelo Gama de Abreu, Paulo André Freire Magalhães

Introduction: This pilot randomized trial evaluated the feasibility of the Manual Diaphragm Release Technique (MDRT) in neurocritical patients on invasive mechanical ventilation (IMV) and explored its immediate effects on diaphragmatic kinematics to inform future trials.

Methods: Adult neurocritical patients receiving IMV and ventilated in an assisted mode (pressure-support ventilation, PSV) at the time of enrollment were randomized to receive a single session of MDRT plus standard physiotherapy vs. a sham maneuver plus standard physiotherapy. The primary outcome was the feasibility of applying MDRT in neurocritical care patients under IMV, operationalized by the recruitment rate, protocol adherence, and incidence of intervention-related adverse events. The exploratory secondary outcomes were immediate diaphragmatic kinematics (contraction and relaxation velocities and inspiratory and expiratory excursions), which were measured by ultrasound to provide preliminary effect-size estimates for future trials.

Results: Twenty neurocritical patients (10 in each group) were randomized and all completed the protocol. Baseline characteristics were comparable between groups. The study demonstrated high feasibility with 80% recruitment rate, 100% adherence, and a mean intervention time of 6.2 ± 1.1 min. No adverse events were observed during or after the intervention. Adjusted analyses revealed no detectable differences in diaphragmatic kinematics between groups after the single session. The adjusted mean differences were 0.1 mm/s (95% CI: -0.3 to 0.5; p = 0.50) for contraction velocity and 0.2 mm/s (95% CI: -0.05 to 0.45; p = 0.11) for relaxation velocity. For diaphragmatic excursion, the difference was 0.5 mm (95% CI: -1.2 to 2.2; p = 0.55) during inspiration and 1.0 mm (95% CI: -0.1 to 2.1; p = 0.08) during expiration.

Conclusions: MDRT was found to be feasible for use in neurocritical patients under mechanical ventilation. Although no immediate effects on diaphragm kinematics were detected, these preliminary findings support the rationale for larger, adequately powered trials to further investigate cumulative or long-term effects.

Trial registration: The trial is registered in ReBEC-Brazilian Registry of Clinical Trials under ID: RBR-3ngffwr.

简介:本随机试验评估了手动膈肌释放技术(MDRT)在神经危重症患者有创机械通气(IMV)中的可行性,并探讨了其对膈肌运动学的直接影响,为未来的试验提供信息。方法:在入组时接受IMV和辅助通气(压力支持通气,PSV)的成年神经危重症患者随机接受单次MDRT加标准物理治疗与假操作加标准物理治疗。主要结果是在IMV下的神经危重症患者中应用MDRT的可行性,通过招募率、方案依从性和干预相关不良事件的发生率进行操作。探索性次要结果是直接膈肌运动学(收缩和松弛速度以及吸气和呼气偏移),通过超声测量,为未来的试验提供初步的效应大小估计。结果:随机选取神经危重症患者20例(每组10例),全部完成治疗方案。各组间基线特征具有可比性。该研究具有很高的可行性,80%的招募率,100%的依从性,平均干预时间为6.2±1.1 min。在干预期间或之后没有观察到不良事件。调整后的分析显示,单次训练后各组间膈肌运动无明显差异。收缩速度调整后的平均差异为0.1 mm/s (95% CI: -0.3至0.5;p = 0.50),松弛速度调整后的平均差异为0.2 mm/s (95% CI: -0.05至0.45;p = 0.11)。对于膈肌偏移,吸气时的差异为0.5 mm (95% CI: -1.2至2.2;p = 0.55),呼气时的差异为1.0 mm (95% CI: -0.1至2.1;p = 0.08)。结论:MDRT应用于神经危重症患者机械通气是可行的。虽然没有检测到对膈肌运动学的直接影响,但这些初步发现支持了更大规模、足够有力的试验的基本原理,以进一步研究累积或长期影响。试验注册:该试验在巴西临床试验注册中心注册,ID: RBR-3ngffwr。
{"title":"Feasibility of the Manual Diaphragm Release Technique in Neurocritical Patients on Mechanical Ventilation: A Pilot Randomized Controlled Trial.","authors":"Elis Fernanda Araújo Lima de Oliveira, Helga Cecília Muniz de Souza, Heitor Fernandes Silveira Cavalini, Fabianne Maisa de Novaes Assis Dantas, Victor Ribeiro Neves, Fernando de Aguiar Lemos, Marcelo Gama de Abreu, Paulo André Freire Magalhães","doi":"10.3390/medsci14010001","DOIUrl":"10.3390/medsci14010001","url":null,"abstract":"<p><strong>Introduction: </strong>This pilot randomized trial evaluated the feasibility of the Manual Diaphragm Release Technique (MDRT) in neurocritical patients on invasive mechanical ventilation (IMV) and explored its immediate effects on diaphragmatic kinematics to inform future trials.</p><p><strong>Methods: </strong>Adult neurocritical patients receiving IMV and ventilated in an assisted mode (pressure-support ventilation, PSV) at the time of enrollment were randomized to receive a single session of MDRT plus standard physiotherapy vs. a sham maneuver plus standard physiotherapy. The primary outcome was the feasibility of applying MDRT in neurocritical care patients under IMV, operationalized by the recruitment rate, protocol adherence, and incidence of intervention-related adverse events. The exploratory secondary outcomes were immediate diaphragmatic kinematics (contraction and relaxation velocities and inspiratory and expiratory excursions), which were measured by ultrasound to provide preliminary effect-size estimates for future trials.</p><p><strong>Results: </strong>Twenty neurocritical patients (10 in each group) were randomized and all completed the protocol. Baseline characteristics were comparable between groups. The study demonstrated high feasibility with 80% recruitment rate, 100% adherence, and a mean intervention time of 6.2 ± 1.1 min. No adverse events were observed during or after the intervention. Adjusted analyses revealed no detectable differences in diaphragmatic kinematics between groups after the single session. The adjusted mean differences were 0.1 mm/s (95% CI: -0.3 to 0.5; <i>p</i> = 0.50) for contraction velocity and 0.2 mm/s (95% CI: -0.05 to 0.45; <i>p</i> = 0.11) for relaxation velocity. For diaphragmatic excursion, the difference was 0.5 mm (95% CI: -1.2 to 2.2; <i>p</i> = 0.55) during inspiration and 1.0 mm (95% CI: -0.1 to 2.1; <i>p</i> = 0.08) during expiration.</p><p><strong>Conclusions: </strong>MDRT was found to be feasible for use in neurocritical patients under mechanical ventilation. Although no immediate effects on diaphragm kinematics were detected, these preliminary findings support the rationale for larger, adequately powered trials to further investigate cumulative or long-term effects.</p><p><strong>Trial registration: </strong>The trial is registered in ReBEC-Brazilian Registry of Clinical Trials under ID: RBR-3ngffwr.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"14 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-Induced Intestinal Angioedema: A Disproportionality Analysis Using the United States Food and Drug Administration Adverse Event Reporting System Database and Literature Review. 药物性肠血管性水肿:使用美国食品和药物管理局不良事件报告系统数据库和文献综述的歧化分析。
IF 4.4 Q1 Medicine Pub Date : 2025-12-18 DOI: 10.3390/medsci13040327
Poovizhi Bharathi Rajaduraivelpandian, Rashmi R Rao, Ashwin Kamath

Background: Intestinal angioedema is an important drug-induced adverse effect that is often misdiagnosed due to vague and nonspecific symptoms. This study aimed to identify drugs with potential to cause intestinal angioedema by performing a disproportionality analysis, supplemented with literature review.

Methods: Using OpenVigil, we extracted relevant individual case safety reports from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Drugs with signal of disproportionate reporting (SDR) of intestinal angioedema were identified. A literature review was performed using PubMed and Embase databases to identify potential suspect drugs.

Results: During 2004-2024, 303 cases of intestinal angioedema were reported to FAERS. Fourteen suspect medications showed SDR; of these, seven drugs were also reported in the literature to have caused intestinal angioedema, including angiotensin-converting enzyme inhibitors, losartan, and acetylsalicyclic acid. A literature search identified 89 relevant articles, providing details of 121 cases. Some drugs linked to intestinal angioedema in the literature did not show SDR.

Conclusions: Disproportionality analysis as well as a literature review showed that most patients were middle-aged females on antihypertensive therapy. The results will assist health professionals in determining the temporal association of acute abdomen with the suspected drug, potentially avoiding unnecessary interventions and their attendant complications.

背景:肠血管性水肿是一种重要的药物引起的不良反应,常因症状模糊和非特异性而被误诊。本研究旨在通过进行歧化分析,并辅以文献综述,确定可能引起肠血管性水肿的药物。方法:使用OpenVigil软件,从美国食品和药物管理局不良事件报告系统(FAERS)数据库中提取相关的个案安全报告。鉴定出具有肠血管性水肿不成比例报告信号(SDR)的药物。使用PubMed和Embase数据库进行文献综述,以确定潜在的可疑药物。结果:2004-2024年间,FAERS报告了303例肠血管性水肿。14种疑似药物显示SDR;其中,文献中也报道了7种药物引起肠血管性水肿,包括血管紧张素转换酶抑制剂、氯沙坦和乙酰水杨酸。文献检索确定了89篇相关文章,提供了121例病例的详细信息。文献中一些与肠血管性水肿相关的药物未显示SDR。结论:歧化分析及文献复习显示,接受降压治疗的患者以中年女性居多。结果将有助于卫生专业人员确定急腹症与可疑药物的时间关联,潜在地避免不必要的干预及其伴随的并发症。
{"title":"Drug-Induced Intestinal Angioedema: A Disproportionality Analysis Using the United States Food and Drug Administration Adverse Event Reporting System Database and Literature Review.","authors":"Poovizhi Bharathi Rajaduraivelpandian, Rashmi R Rao, Ashwin Kamath","doi":"10.3390/medsci13040327","DOIUrl":"10.3390/medsci13040327","url":null,"abstract":"<p><strong>Background: </strong>Intestinal angioedema is an important drug-induced adverse effect that is often misdiagnosed due to vague and nonspecific symptoms. This study aimed to identify drugs with potential to cause intestinal angioedema by performing a disproportionality analysis, supplemented with literature review.</p><p><strong>Methods: </strong>Using OpenVigil, we extracted relevant individual case safety reports from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Drugs with signal of disproportionate reporting (SDR) of intestinal angioedema were identified. A literature review was performed using PubMed and Embase databases to identify potential suspect drugs.</p><p><strong>Results: </strong>During 2004-2024, 303 cases of intestinal angioedema were reported to FAERS. Fourteen suspect medications showed SDR; of these, seven drugs were also reported in the literature to have caused intestinal angioedema, including angiotensin-converting enzyme inhibitors, losartan, and acetylsalicyclic acid. A literature search identified 89 relevant articles, providing details of 121 cases. Some drugs linked to intestinal angioedema in the literature did not show SDR.</p><p><strong>Conclusions: </strong>Disproportionality analysis as well as a literature review showed that most patients were middle-aged females on antihypertensive therapy. The results will assist health professionals in determining the temporal association of acute abdomen with the suspected drug, potentially avoiding unnecessary interventions and their attendant complications.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"13 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12735144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical sciences (Basel, Switzerland)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1